Sensei Biotherapeutics, Inc. (FTH) – What Are Researchers Thinking About This Stock?

Shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH) have received a consensus rating of “Moderate Buy” from the sixteen brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, twelve have given a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $56.25.

FTH has been the subject of several analyst reports. Raymond James Financial began coverage on Sensei Biotherapeutics in a research note on Friday, July 31st. They set an “outperform” rating and a $56.00 price objective for the company. Robert W. Baird assumed coverage on Sensei Biotherapeutics in a report on Friday, June 26th. They set an “outperform” rating and a $57.00 price target for the company. JonesTrading started coverage on shares of Sensei Biotherapeutics in a research report on Tuesday, August 4th. They issued a “buy” rating and a $55.00 price objective on the stock. BTIG Research reiterated a “buy” rating and issued a $55.00 price objective on shares of Sensei Biotherapeutics in a research report on Thursday, July 16th. Finally, HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Sensei Biotherapeutics in a research note on Tuesday, August 11th.

Hedge Funds Weigh In On Sensei Biotherapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC acquired a new stake in shares of Sensei Biotherapeutics in the 2nd quarter valued at approximately $307,000. Renaissance Technologies LLC grew its holdings in Sensei Biotherapeutics by 178.2% during the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after acquiring an additional 20,525 shares during the period. Bank of America Corp DE grew its holdings in Sensei Biotherapeutics by 10,692.5% during the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after acquiring an additional 32,719 shares during the period. Stempoint Capital LP purchased a new position in Sensei Biotherapeutics in the first quarter worth $4,188,000. Finally, Alyeska Investment Group L.P. purchased a new position in Sensei Biotherapeutics in the second quarter worth $3,610,000. Institutional investors and hedge funds own 10.50% of the company’s stock.

Sensei Biotherapeutics Price Performance

FTH opened at $19.44 on Tuesday. Sensei Biotherapeutics has a one year low of $7.45 and a one year high of $42.14. The firm has a market capitalization of $502.33 million, a PE ratio of -0.14 and a beta of -0.29. The business’s 50-day moving average price is $31.21.

Sensei Biotherapeutics (NASDAQ:FTH) last announced its earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($5.04) by $2.20. As a group, equities research analysts forecast that Sensei Biotherapeutics will post -13.69 earnings per share for the current fiscal year.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies designed to activate the immune system against tumors. The company’s approach is intended to address immune suppression within the tumor microenvironment and potentially improve patients’ responses to existing cancer treatments.

Sensei’s pipeline has included antibody-based and vaccine-based immunotherapies. Its lead programs have included SNS-101, an antibody designed to target the VISTA immune checkpoint, and earlier ImmunoPhage-based programs intended to stimulate tumor-specific immune responses.